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Abstract
Purpose: To investigate dexamethasone intravitreal implant 
0.7 mg (DEX implant) for the treatment of diabetic macular 
oedema (DME) refractory to anti-vascular endothelial growth 
factor (anti-VEGF) therapy and evaluate predictive factors. 
Methods: Two-centre retrospective interventional case se-
ries, including 40 eyes of 31 patients treated with DEX im-
plant for at least 2 consecutive cycles. Results: Mean ± SD 
intervals from implantation to recurrence in the first (4.2 ± 
1.0 months) and second cycles (4.0 ± 0.9 months) were not 
significantly different. Best corrected visual acuity improved 
significantly (p < 0.001) by 7.0 ± 8.4 letters from baseline to 
month 2, and by 5.1 ± 6.9 letters between the first and sec-
ond cycles. Central retinal thickness reduction 2 months af-
ter implantation was greater after the first (–194 ± 172 µm) 
than the second cycle (–134 ± 150 µm). Ellipsoid zone-exter-
nal limiting membrane (EZ-ELM) disruption score decreased 
from 1.39 ± 1.16 at baseline to 1.24 ± 1.16 (p = 0.0832) after 
cycle 1 and remained stable 2 months after cycle 2. Eyes with 
persisting severe EZ-ELM disruption (score >2, n = 10) 2 
months after the first DEX implant showed significantly (p = 
0.0153) smaller visual acuity (VA) gains than eyes with less 
severe (score ≤2) EZ-ELM disruption. Conclusion: Repeated 
intravitreal DEX injections with average intervals of 4 months 
are valuable in patients with DME refractory to anti-VEGF 
therapy. Disorganization of outer retinal layers (EZ-ELM) may 
predict smaller VA gains if evaluated after initial reduction of 
macular oedema. © 2018 S. Karger AG, Basel
Introduction
Diabetic macular oedema (DME) is one of the leading 
causes of vision loss and blindness in patients with diabe-
tes [1]. Laser photocoagulation was the standard of care 
for the treatment of DME until the availability of anti-
vascular endothelial growth factor (anti-VEGF) thera-
pies. Studies have demonstrated improved visual and an-
atomical outcomes with anti-VEGF therapies, with well-
tolerated safety profiles [2–6]. However, a retrospective 
analysis of the RIDE/RISE studies showed that after 36 
months of monthly treatment with ranibizumab, 18% of 
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patients (n = 88/500) still needed further high-frequency 
treatment defined as >7 injections per year [7], indicating 
that some patients may be refractory to anti-VEGF treat-
ment. 
DME features characteristics of chronic, local inflam-
matory response in patients who do not respond to anti-
VEGF therapy or need very frequent treatment; there-
fore, inflammatory mediators other than VEGF may also 
play a role in sustaining DME [8]. Vitreous fluid from 
patients with DME shows evidence of active inflamma-
tion, containing elevated concentrations of many differ-
ent inflammatory and pro-inflammatory mediators [9–
11]. Therefore, treatment targeting these inflammatory 
or pro-inflammatory mediators may improve disease 
outcomes. 
Intravitreal triamcinolone acetonide, a corticosteroid, 
has been shown to be effective in treating anti-VEGF-re-
sistant DME, but only in the short term [12]. The dexa-
methasone intravitreal implant 0.7 mg (DEX implant, 
Ozurdex®, Allergan Inc., Irvine, CA, USA), a long-acting 
sustained-release corticosteroid [13], has been shown to 
be effective in treating DME [14–17]. Upon treatment 
with DEX implant, pro-permeability factors were re-
duced in aqueous samples [18]. 
Most studies and case series have reported outcomes 
either following a single DEX implant [14, 17, 19, 20] or 
retreatment with DEX implant after 6 months [15, 16]. 
One small retrospective analysis reported the use of re-
peated as-needed DEX implants [21]. 
Until now, there have been limited data regarding pre-
dictive morphological features in DME that can identify 
patients who may benefit from DEX implant treatment. 
Coscas et al. [22] reported a case series of 9 patients with 
macular oedema due to retinal vein occlusion and showed 
that visual acuity (VA) in eyes with interrupted or thick-
ened photoreceptor inner and outer segment junctions 
(ellipsoid zone, EZ) at 3 months was worse than in eyes 
with a normal EZ. Bansal et al. [23] suggested that the 
preservation of external limiting membrane (ELM) and 
EZ in eyes with uveitic cystoid macular oedema might 
carry a better visual prognosis after DEX implantation, 
whereas retinal thickness, height of cysts, and presence of 
serous retinal detachment did not affect the final visual 
outcome. So far, there are no reports that spectral domain 
optical coherence tomography (SD-OCT) scans of pa-
tients with DME and a DEX implant show any features 
that would predict the outcome of the treatment, but it 
seems likely that there might be a correlation [24, 25]. 
This multicentre retrospective case series study inves-
tigated the effect of as-needed treatment with repeated 
DEX implants in patients with DME not responsive to 
anti-VEGF therapy and evaluated predictive morpholog-
ical features. 
Materials and Methods 
Study Design
This was a multicentre (2 centres), retrospective, consecutive 
case series performed at Vista Klinik, Binningen, and Inselspital, 
Bern, Switzerland, to investigate the use of the DEX implant in 
routine clinical use for the treatment of DME in patients not re-
sponding to anti-VEGF therapy, and to identify features using SD-
OCT that may predict treatment outcome. 
The study was carried out in line with the Declaration of Hel-
sinki, and with guidelines of the International Conference on Har-
monisation, Good Clinical Practice, and the Humanforschungsge-
setz (law on research on human beings in Switzerland). Ethics ap-
proval number: LEK EKNZ 2014-360, EK BE 308/14. 
Written informed consent was obtained from each participat-
ing patient for retrospective analyses of patient data and use of 
imaging material obtained from the participating centres.
Patients
The study retrospectively evaluated all eyes with chronic DME 
(confirmed with fluorescein angiography) treated with the DEX 
implant for at least 2 consecutive cycles (i.e., until recurrence of 
symptoms after second implant) from 2011 to 2015. All patients 
had been pre-treated with routine anti-VEGF therapy and re-
quired either very frequent treatment (monthly) or failed to show 
morphological improvement under anti-VEGF therapy. Lesions 
that had not been fully documented were excluded. 
Outcomes and Assessments 
Mean treatment interval from implantation to recurrence, de-
fined as recurrence of sub- or intra-retinal fluid in OCT, after the 
first or second injection with DEX was the primary endpoint of the 
study. Secondary outcome measures included mean change in best 
corrected visual acuity (BCVA) and central retinal thickness (CRT) 
from baseline to month 2, as well as time of recurrence after each 
injection, and comparison between the two consecutive injections 
with DEX; mean EZ-ELM disruption score at baseline and 2 months 
after first and second implant and its correlation with VA outcome; 
mean number of hyperreflective foci (HRF) at baseline and 2 
months after first and second implant and its correlation with VA 
outcomes; and safety, including cataract progression, mean change 
in intraocular pressure (IOP) from baseline to month 2, and time 
of recurrence for each cycle and between cycles. BCVA was either 
measured as 4-month VA following ETDRS refraction protocol or 
as Snellen 4- or 6-month BCVA and transferred into ETDRS letter 
score. IOP was measured using Goldmann applanation tonometry.
EZ-ELM disruption, as measured by SD-OCT (Heidelberg En-
gineering, Inc., Heidelberg, Germany), was evaluated as the mean 
of the horizontal and vertical scans and graded as: 0 (no disruption 
in 1-mm centre), 1 (mild disruption <1/4 within 1-mm centre), 2 
(1/4 to 3/4 disruption within 1-mm centre), and 3 (>3/4 disruption 
within 1-mm centre). HRF number (central 1 mm) was calculated 
as the sum of the HRF numbers within the horizontal and vertical 
scans using SD-OCT. 
DEX Implant in DME and SD-OCT 
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SD-OCT scans were acquired using established protocols com-
promising 19 or 49 6-mm horizontal scans (volume scan) in a fol-
low-up modus (high speed modus, 9 frames, 512 A-scans) as well 
as the 6-mm star scan (high speed modus, 9 frames, 512 A-scans). 
For thickness analyses, a manual correction of the automated seg-
mentations was performed if any segmentation errors were pres-
ent. For analyses which related to the central vertical and horizon-
tal scan, the 6-mm star scan was used.
Statistical Analysis
For the variables, mean ± standard deviation (SD) or percent-
ages were calculated. Statistical analyses were performed with SPSS 
version 23.0 for Windows (SPSS; Chicago, IL, USA). To compare 
follow-up with baseline values, a 2-sided t test was performed. The 
comparison of before and after treatment values in the same group 
was performed with the t test for dependent variables, while inter-
group comparisons were performed with the t test for independent 
variables. A p value <0.05 was considered statistically significant.
Statistical analyses were only performed with data from the first 
two treatment cycles due to the decreasing number of subjects 
from cycle 3 onwards.
Results
Patient Characteristics and Demographics
Overall, 40 DME lesions from 31 patients were evalu-
ated in this analysis (23 in Binningen; 17 in Bern). One 
further patient was not included in this analysis owing to 
loss of follow-up during the second cycle. The mean age 
of patients was 68.3 ± 8.8 years and the mean BCVA and 
CRT at baseline were 53.7 ± 16.8 letters and 569 ± 251 µm, 
respectively. Patient baseline characteristics are provided 
in Table 1.
Mean Treatment Interval for Each Cycle 
Overall, the eyes received a mean of 3.72 ± 2.41 DEX 
implants (range 2–13) during the study period. The mean 
interval from implantation to recurrence of DME in the 
first cycle (4.2 ± 1.0 months) and the second cycle (4.0 ± 
0.9 months) was not significantly different (p = 0.419). In 
further cycles, mean interval from implantation to recur-
rence of DME was similar to that observed in the first 2 
cycles (4.3 ± 1.2 and 4.1 ± 0.5 months in the third and 
fourth cycles, respectively). 
Change in BCVA between First and Second Cycles
Mean VA improved significantly (p < 0.001) by 7.0 ± 
8.4 letters from baseline to month 2 and by 5.1 ± 6.9 let-
ters within the first and second cycle. Mean VA observed 
at the baseline of the first cycle (BL1, 53.7 ± 16.8 letters) 
was not significantly different from that observed at the 
baseline of the second cycle (BL2; 54.2 ± 16.9 letters, p = 
0.729) (Fig. 1a). Similarly, mean VA observed 2 months 
after implantation in the first and second cycles (60.7 ± 
16.4 and 59.3 ± 17.0 letters, p = 0.164), and during recur-
rence between the first and second cycles (54.8 ± 16.6 and 
52.9 ± 17.3 letters, respectively; p = 0.193) was not sig-
nificantly different. 
Two months after implantation, eyes with lower base-
line VA (≤39 letters) tended to show a greater VA gain 
than eyes with higher baseline VA (≥60 letters) in the first 
cycle (p = 0.073, see Table 2); however, no such differ-
ences were noted in the second cycle. 
VA outcomes for pseudophakic and phakic eyes are 
shown in Figure 1b, c. In phakic eyes, VA was higher at 
Age, years 68.3±8.8
Diabetes type, % type 2 100
Lens status
Phakic, n (%) 6 (15)
Pseudophakic, n (%) 34 (85)
Pretreatment intravitreal
Percent pretreated with anti-VEGF 100
Number of anti-VEGF treatments (ranibizumab and/or
bevacizumab) 13.0±8.8 (range 3–35)
Percent pretreated with triamcinolone 22.5
Number of triamcinolone treatments 0.4±0.9 (range 0–4)
BCVA, ETDRS letter score 53.7±16.8 
CRT, µm 569±251
IOP, mm Hg 15.1±3.3 
Unless otherwise stated, results are expressed as mean ± SD. BCVA, best corrected 
visual acuity; CRT, central retinal thickness; EDTRS, early treatment for diabetic 
retinopathy study; IOP, intraocular pressure; VEGF, vascular endothelial growth factor.
Table 1. Baseline characteristics (n = 40)
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baseline (≥60 letters); but it then dropped to <60 letters 2 
months after DEX implant during the first and second 
cycle (Fig. 1b, c).
Change in CRT: Comparison between First and 
Second Cycles
DEX significantly reduced mean CRT from baseline to 
month 2 within each of the two cycles (1st cycle: from 569 
± 251 to 375 ± 199 µm, p < 0.001; 2nd cycle: from 513 ± 
241 to 379 ± 183 µm, p < 0.001). Mean CRT at baseline 
for the first cycle (569 ± 251 µm) was significantly greater 
than mean CRT at baseline for the second cycle (513 ± 
241 µm; p = 0.047) (Fig.  2). Mean CRT reduction ob-
served 2 months after DEX implantation in the first cycle 
(–194 ± 172 µm) was significantly greater than that ob-
served in the second cycle (–134 ± 150 µm, p = 0.025). 
However, there was no significant difference in mean 
CRT values 2 months after the first (375 ± 199 µm) and 
second (379 ± 183 µm) implants (p = 0.833), or after re-
currence in the 2 cycles (first: 498 ± 238 µm and second: 
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Fig. 1. Change in visual acuity from baseline to 2 months after each treatment and at recurrence for all eyes (a); 
pseudophakic eyes (b); and phakic eyes (c). BL, baseline. * p < 0.001 from baseline to post-implant.
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Table 2. Visual acuity gain in 2 implant cycles and assessment of correlation with baseline parameters in patients 
with DME (t test for independent variables)
Parameter VA gain 2 months after 1st implant VA gain 2 months after 2nd implant 
(calculated from baseline of 2nd cycle)
mean ± SD p value mean ± SD p value
Baseline BCVA
≤39 letters 12.5±10.3 (n = 11) 0.073 6.6±7.9 (n = 11) 0.3533
≥60 letters 6.9±5.9 (n = 18) 4.4±4.6 (n = 18)
Baseline CRT
≤400 µm 3.9±3.8 (n = 10) 0.0343 2.2±2.6 (n = 10) 0.0173
≥600 µm 11.1±9.2 (n = 10) 8.7±7.4 (n = 10)
Baseline EZ-ELM disruption
Score >2 5.8±6.3 (n = 11) 0.5773 2.4±8.2 (n = 11) 0.1257
Score ≤2 7.5±9.6 (n = 29) 6.1±6.2 (n = 29)
EZ-ELM disruption after oedema reduction (2 months after 1st implant)
Score >2 5.8±6.7 (n = 10) 0.6225 0.6±6.0 (n = 10) 0.0153
Score ≤2 7.4±9.4 (n = 30) 6.6±6.6 (n = 30) 
Hyperreflective foci 
>15 3.1±12.0 (n = 8) 0.1638 5.5±11.0 (n = 8) 0.8478
≤15 8.0±7.7 (n = 32) 5.0±5.7 (n = 32)
BCVA, best corrected visual acuity; CRT, central retinal thickness; DME, diabetic macular oedema; EZ-ELM-
ELM, ellipsoid zone-external limiting membrane; SD, standard deviation. 
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Fig. 2. Change in central retinal thickness of all eyes 2 months after each treatment and at recurrence. BL, base-
line.
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513 ± 223 µm, p = 0.445). Eyes with low baseline CRT 
(≤400 µm) had significantly smaller VA gains than eyes 
with higher CRT (≥600 µm) after the first and second 
cycle (p = 0.0343 and p = 0.0173, respectively; Table 2). 
SD-OCT Morphological Findings and Their 
Correlation to VA Outcome
The mean EZ-ELM disruption score of 1.39 ± 1.16 at 
baseline decreased to 1.24 ± 1.16 at 2 months after the first 
DEX implant (p = 0.0832) and remained stable 2 months 
after the second DEX implant (1.24 ± 1.10). Severe EZ-
ELM disruption at baseline (score >2) did not seem to be 
predictive for VA gain 2 months after the first and the 
second implant: VA gains did not differ significantly be-
tween eyes with severe EZ-ELM disruption at baseline 
(n = 11, score >2) and those with no or less severe EZ-
ELM disruption at baseline (score ≤2; n = 29; Table 2). 
However, 2 months after the first DEX implant, eyes with 
persisting severe EZ-ELM disruption (score >2, n = 10) 
showed significantly smaller (p = 0.0153) VA gains than 
did eyes with less severe (score ≤2) EZ-ELM disruption 
(0.6 ± 6.0 vs. 6.6 ± 6.6 letters, respectively, Table 2). 
The mean number of HRF within the central 1 mm per 
SD-OCT was 10.9 ± 7.9 at baseline, which decreased 
slightly to 9.1 ± 7.6 2 months after the first DEX implant 
(p = 0.0775) and remained stable after the second implant 
(9.4 ± 7.0, p = 0.2285). 
There was no significant difference in VA gains be-
tween eyes with high baseline HRF (>15 HRF, n = 8) and 
those with no or fewer HRF (≤15 HRF, n = 32) in cycle 1 
(p = 0.1638) and cycle 2 (p = 0.8478) (Table 2). High HRF 
at baseline seemed not to be predictive for VA gain 2 
months after the first and second DEX implant. Similar 
results were seen after excluding the phakic eyes from 
analysis (p = 0.8962). In eyes with high HRF (>15, n = 8) 
and those with no or less HRF (≤15, n = 32), mean VA 
gains 2 months after first implant were found to be simi-
lar (4.6 ± 7.6 and 5.2 ± 6.7 letters, p = 0.8044; after exclu-
sion of phakic eyes p = 0.8962). 
Safety
Intraocular Pressure
Baseline mean IOP of 15.1 ± 3.3 mm Hg increased sig-
nificantly to 18.1 ± 5.4 mm Hg 2 months after the first 
DEX implant (p < 0.001). However, there was no signifi-
cant difference in IOP from baseline at the first recur-
rence (15.4 ± 4.1 mm Hg, p = 0.680). Overall, 8 eyes (20%) 
were under topical IOP-lowering treatment at the end of 
the first cycle. For 2 eyes, the pre-existing topical IOP-
lowering treatment was continued; for 2 eyes, the pre-
existing topical IOP-lowering treatment was expanded by 
adding another substance; and for 4 eyes, the topical IOP-
lowering treatment was newly established and continued 
after the treatment cycle finished. 
IOP in the second cycle showed a similar trend to that 
of the first cycle, with mean IOPs of 15.2 ± 3.7 mm Hg at 
baseline, 18.4 ± 7.9 mm Hg at 2 months after implant, and 
15.9 ± 4.5 mm Hg at recurrence. When compared with 
the baseline values, 2-month values and recurrence values 
demonstrated no significant differences between the first 
2 cycles. Of 8 eyes in the first cycle, the topical IOP-low-
ering treatment was expanded for 3 eyes by adding an-
other substance, 2 eyes received filtration surgery, and 3 
were continued on their topical IOP-lowering treatment 
during the second cycle. Topical IOP-lowering treatment 
was newly established for 2 more eyes during the second 
cycle. During further cycles, topical treatment was 
stopped for 2 eyes, whereas it was newly established in 2 
other eyes. There were no further changes in IOP man-
agement, and no eyes needed further filtration surgery.
Cataract Progression
At baseline, only 6 out of 40 (15%) eyes were phakic. 
All these patients experienced cataract progression dur-
ing follow-up and 1 eye received cataract surgery during 
the first cycle. Patients with phakic eyes (6/40) were 
younger (mean age: 58.8 ± 7.7 years) than the total pop-
ulation (see Table 1, p = 0.0173), and these eyes showed 
significantly smaller VA changes 2 months after the first 
DEX implant compared with pseudophakic eyes (–0.3 
± 11.3 vs. 8.3 ± 7.7 letters, p = 0.0238). One eye that re-
ceived cataract surgery during the first cycle was includ-
ed in the pseudophakic group for analysis of the second 
cycle. In the remaining 5 phakic eyes, a non-significant 
trend towards smaller gains in VA was observed com-
pared with pseudophakic eyes (1.2 ± 9.2 vs. 5.6 ± 6.5 
letters, p = 0.1809). No other adverse events were ob-
served.
Discussion
In this study, VA and CRT improved 2 months after 
DEX implant for 2 consecutive cycles with as-needed 
DEX treatment in eyes with DME refractory to anti-
VEGF therapy. No additional increase in cataract pro-
gression or IOP-related surgeries was observed. Patients 
with low VA and high CRT seemed to benefit the most 
from DEX treatment. Of the predictive factors assessed, 
disorganization of outer retinal layers (EZ-ELM disrup-
DEX Implant in DME and SD-OCT 
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tion) was predictive of lower VA gain after DEX implant 
in eyes with less severe oedema. 
Alternative therapies are required for treatment of 
eyes with DME refractory to anti-VEGF treatment. Stud-
ies comparing the DEX implant to anti-VEGF treatment 
in DME showed similar gains in VA after 1 year of DEX 
treatment with reduced treatment rates (2.7/12 months) 
compared with patients receiving bevacizumab (8.6/12 
months) [26]. In a prospective study, patients with refrac-
tory diffuse DME treated with DEX implant showed sig-
nificant (p < 0.001) improvement in VA of 5–7 ETDRS 
letters until 6 months after implantation [27]. Similar sig-
nificant improvement (p = 0.03) in VA 2 months after 
DEX implant (as monotherapy or combined with other 
treatments) was also reported by Gutierrez-Benitez et al. 
[28] in patients with DME refractory to ranibizumab. 
Overall, these studies reflect our findings that patients 
with DME refractory to anti-VEGF treatment can benefit 
from DEX treatment.
CRT was significantly reduced (p < 0.001) along with 
VA improvement after DEX implant in two multicentre, 
randomised studies over 3 years [15]. In our study, CRT 
decreased significantly 2 months after the first and sec-
ond cycles. Although CRT was significantly greater at 
baseline 1 than at baseline 2, this may be because re-treat-
ment may have occurred a little earlier than primary DEX 
treatment due to the regular follow-up. 
In clinical practice, the average number of DEX im-
plants has been recorded at 2.3–2.5 per year [29]. Our 
results show that re-treatment with DEX after recurrence 
continued to improve VA and CRT. Improvements in 
VA after re-treatment have also been seen in other studies 
[30]. 
IOP needs to be carefully monitored after DEX im-
plants but can be managed by topical IOP-lowering treat-
ment in most patients. In our study, an increase in IOP 
was observed 2 months after treatment in both treatment 
cycles. Similar results were reported by Totan et al. [31] 
who showed a significant increase from baseline in IOP 
at 1 and 3 months (p ≤ 0.04) after implant; however, these 
were well controlled with topical treatment. Similar to 
our findings, Maturi et al. [30] reported a non-cumulative 
increase in IOP after sequential implants. 
We found a non-significant trend of VA gains to be 
greater for eyes with low baseline VA (≤39 letters) than 
for eyes with high baseline VA (≥60 letters). Similarly, 
Bressler et al. [32] reported significantly (p < 0.001) larg-
er gains in VA in eyes with low baseline VA scores com-
pared with those in eyes with higher baseline VA scores. 
The lack of significance in our study may be due in part 
to the low patient numbers. These data suggest that pa-
tients with low VA not responding to anti-VEGF may 
particularly benefit from DEX treatment.
In eyes with low baseline CRT (≤400 µm), the VA 
gains within the first and second cycle were smaller than 
those in eyes with higher CRT (≥600 µm). In 2013, the 
National Institute Health and Care Excellence (NICE) in 
the United Kingdom recommended the use of anti-VEGF 
treatment for DME, especially in the subgroup of patients 
with CRT >400 μm [33]. This recommendation was based 
on a clinical trial that demonstrated greater improve-
ments in VA and CRT in eyes with CRT >400 μm at base-
line than those with CRT of <400 μm [34]. Similar base-
line parameters may also affect treatment outcomes with 
DEX in patients with chronic DME not responding to 
anti-VEGF treatment. Our results suggest that patients 
with high baseline CRT not responding to anti-VEGF 
may benefit from DEX treatment to a greater degree than 
those with lower CRT at baseline.
Standard treatment for DME involves repetitive, inva-
sive intraocular injections, increasing the burden on pa-
tients, physicians and healthcare resources [35]. Bio-
markers that could predict the effect of a therapy on fu-
ture VA in eyes with DME could improve risk assessment, 
management decisions, and selection of eyes for clinical 
studies [35]. Disorganization of inner retinal layers as a 
predictor for VA outcome in DME within a cohort of 
mostly anti-VEGF- and/or laser-treated eyes was report-
ed in a retrospective study by Sun et al. [35]. However, in 
our study, severe EZ-ELM disruption at baseline (score 
>2) was not associated with VA gain 2 months after the 
first or second DEX implant. Furthermore, no significant 
difference was noted between VA gains of eyes with se-
vere EZ-ELM disruption at baseline (score >2) and those 
with no or less severe EZ-ELM disruption at baseline 
(score ≤2). In the patient population studied by Sun et al., 
mean baseline CRT (408 µm) was much lower than that 
observed in our study (569 µm), indicative of less severe 
macular oedema. The EZ-ELM disruption is more diffi-
cult to evaluate in eyes with more severe oedema, and this 
may explain the lack of correlation between baseline EZ-
ELM disruption score and VA outcome in our study. This 
may also explain our observation that after reduction of 
macular oedema at 2 months after the first implant, eyes 
with persisting severe EZ-ELM disruption (score >2) had 
a significantly smaller VA gain in the later follow-up. 
Therefore, in a population with severe macular oedema, 
evaluation of disorganization of outer retinal layers 
should be done after reduction of macular oedema as a 
predictor of later outcome.
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HRF have been reported in patients with DME [36]. 
Although the exact origin of these HRF remains un-
known, reduction in HRF was seen after treatment with 
ranibizumab or DEX implant in patients with retinal vas-
cular diseases, including retinal vein occlusions and 
DME [37]. In our study, we found a non-significant 
trend for HRF reduction 2 months after the first DEX 
implant (p = 0.0775); the reduction remained stable for 
2 months after the second implant. This lack of statistical 
significance may be due to the low patient numbers. 
Chatziralli et al. [37] further reported an association of 
the presence of HRF with poor VA in patients with mac-
ular oedema due to retinal vascular diseases. However, 
they did not observe better treatment success if the initial 
number of HRF was larger. In our study, high numbers 
of HRF at baseline (>15) also did not seem predictive for 
VA gain 2 months after the first and second DEX im-
plant. However, our results cannot be directly compared 
with the study by Chatziralli’s group because of the dif-
ferences in total HRF calculations. In our study, total 
HRF numbers refer to the central 1 mm as a sum of the 
central horizontal and vertical scan (see Methods), 
whereas Chatziralli et al. [37] examined the horizontal 
6-mm section with the most HRF present. Furthermore, 
our population consisted of a pre-treated population 
with chronic DME, which is indicated by the circum-
stance that all patients showed HRF within the central 
1 mm.
Some additional predictors that were not assessed in 
this study that may be of interest in the future are micro-
aneurysms in the deep capillary plexus (DCP). Signifi-
cant increases in the density of microaneurysms in DCP 
are observed in patients with DME and may contribute 
to the pathogenesis of DME [38]. Lee et al. [39] reported 
that DME eyes that responded poorly to anti-VEGF 
treatment tended to exhibit greater damage and more 
microaneurysms in the DCP. The study also reported 
that the degree of outer plexiform layer disruption in SD-
OCT corresponds well with the extent of DCP loss in 
DME eyes. Therefore, the extent of DCP loss and the cor-
responding outer plexiform layer disruption could be 
useful predictors of responsiveness to anti-VEGF treat-
ment [39].
Unlike most published studies/case series that evalu-
ated single implant or re-treatment after every 6 months, 
the present study evaluated the effect of treatment with 
repeated as-needed DEX implants for more than 2 
treatment cycles. DEX implants are associated with 
risks including IOP elevation and cataract progression; 
therefore, they are often used as second-line therapy to 
anti-VEGF in DME by many retina specialists [17]. For 
this reason, this study was evaluated in candidates for 
DEX implant who had chronic DME and needed fre-
quent anti-VEGF treatment or who failed to respond to 
anti-VEGF treatment. This is also one of the first stud-
ies to investigate VA predictors, including SD-OCT pa-
rameters, in this population. Limitations of the study 
include the retrospective setting and small patient num-
bers. 
In conclusion, this study shows that repeated intravit-
real injections of DEX implants can successfully improve 
VA and reduce CRT in patients who are refractory to an-
ti-VEGF therapy. The time for DEX re-injection for sub-
sequent treatments should be tailored to each individual 
patient on a case-by-case basis to achieve optimum re-
sults. Patients with lower VA and/or greater CRT might 
benefit from DEX treatment. Disorganization of outer 
retinal layers (EZ-ELM) might predict smaller VA gains 
if evaluated after initial reduction of macular oedema. 
Further prospective studies are needed in this target pop-
ulation to confirm the predictors assessed in this study, to 
investigate other potentially predictive factors that may 
help identify patients who can benefit from early DEX 
treatment, and to compare outcomes in patients with 
DEX implants with outcomes in anti-VEGF non-re-
sponders. 
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